Originally published September 27 2005
Lipitor is no more effective than competitors; sometimes has worse side effects, study says
by Mike Adams, the Health Ranger, NaturalNews Editor
Although Lipitor, by Pfizer, is the world's best-selling cardiovascular drug, a recent German study found that it is no more effective than its competitors or similar drugs that reduce cholesterol, and in some cases, Lipitor has more severe side effects than other statin drugs.
Pfizer Inc.'s cardiovascular treatment Lipitor, the world's best-selling drug, is no more effective than similar drugs and in some cases has worse side effects, according to a study by an independent German institute.
The results come from a survey of previous studies worldwide, rather than new clinical tests on patients.
It was released Saturday by Institut fuer Qualitaet und Wirtschaftslichkeit im Gesundheitswesen.
According to IQWiG, life-prolonging results for patients suffering from chronic coronary heart disease was seen with Merck & Co.'s Zocor and Bristol-Myers Squibb Co.'s Pravastin -- but not with Lipitor.
Jonathan Jones at Pfizer U.K.'s Cardio-Vascular Group said he couldn't comment directly without studying IQWiG's analysis.
However he noted that the side effects of the rival medicines differed, and that any study could yield different answers depending on the weight given to them.
Representatives based at Pfizer's New York headquarters did not return calls Sunday.
In acute diseases, there weren't enough data to prove that any of the group -- Lipitor, Zocor or Pravastin -- was better than the other.
With diabetes mellitus, only Merck's Zocor was shown to prolong life.
After Germany's health insurers introduced a fixed price for Lipitor by the end of 2004, Pfizer asked its patients to pay the difference between the price of Lipitor and the sum that would be paid by health insurers.
Other pharmaceutical companies lowered the price for drugs after the move of the health insurers.
Pfizer then started an advertisement campaign in newspapers, stating that Lipitor is better than other statins, notably that is has fewer side effects at high dosages.
According to consulting firm IMS Health, Lipitor $12 billion worth of Lipitor last year.
Zocor, the world's second-best-selling drug, posted sales of $5.9 billion.
All content posted on this site is commentary or opinion and is protected under Free Speech. Truth Publishing LLC takes sole responsibility for all content. Truth Publishing sells no hard products and earns no money from the recommendation of products. NaturalNews.com is presented for educational and commentary purposes only and should not be construed as professional advice from any licensed practitioner. Truth Publishing assumes no responsibility for the use or misuse of this material. For the full terms of usage of this material, visit www.NaturalNews.com/terms.shtml